Response to Response to Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”

Response to Response to Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”

Saved in:

Bibliographic Details
Main Author:	Matthew K. Wun
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	Journal of Veterinary Internal Medicine
Online Access:	https://doi.org/10.1111/jvim.70019
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Response to Second Letter on Response Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”
by: Marjory B. Brooks, et al.
Published: (2025-03-01)

Letter Regarding “Comparison of 2 Assays for Measuring Serum Total Thyroxine Concentration in Dogs and Cats”
by: Matthew K. Wun
Published: (2025-05-01)

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

Response to Response to Letter Regarding “An Artificial Neural Network‐Based Model to Predict Chronic Kidney Disease in Aged Cats”
by: Matthew K. Wun
Published: (2025-03-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Response to Letter Regarding “Comparison of 2 Assays for Measuring Serum Total Thyroxine Concentration in Dogs and Cats”
by: Ewan D. S. Wolff, et al.
Published: (2025-05-01)

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice
by: II Zotova, et al.
Published: (2017-01-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY
by: Francesco Rodeghiero, et al.
Published: (2023-02-01)

Letter Regarding “An Artificial Neural Network‐Based Model to Predict Chronic Kidney Disease in Aged Cats”
by: Matthew K. Wun
Published: (2025-03-01)

Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China
by: Lingling Fu, et al.
Published: (2025-02-01)

Experts Council Resolution on topical issues in the treatment of patients with idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) and thrombopoietin receptor agonist (avatrombopag)
by: article Editorial
Published: (2022-04-01)

A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia
by: Dandan Chen, et al.
Published: (2022-01-01)

Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)

Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy
by: Konstantina Salveridou, et al.
Published: (2024-09-01)

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01)

Immune thrombocytopenia: clinical manifestation and therapy response. The interim analysis of Russian register of patients with primary immune thrombocytopenia and literature review
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Efficacy and Safety of Recombinant Human Thrombopoietin (rhTPO) on Coagulation Function and Inflammatory Factors in the Treatment of Patients with Sepsis-Related Thrombocytopenia
by: Huijuan Wang MD, et al.
Published: (2025-02-01)

Thrombopoietin: tickling the HSC's fancy
by: Ah Ram Kim, et al.
Published: (2017-11-01)

Identification of Plasma Thrombopoietin Level and Its Significance in Patients with Aplastic Anemia and Myelodysplastic Syndrome
by: Mengying Zhang, et al.
Published: (2023-09-01)

Response and remission after first-line corticosteroid therapy in primary immune thrombocytopenia
by: D Mapimhidze, et al.
Published: (2025-02-01)

Two Refractory Immune Thrombocytopenia Case Reports Showing Responsiveness to Fostamatinib
by: Vanessa Innao, et al.
Published: (2023-01-01)

Response to the Letter to the Editor Regarding “Bicarbonate and Serum Lab Markers as Predictors of Mortality in the Trauma Patient”
by: Matthew M. Talbott, et al.
Published: (2025-02-01)

Response to Second Letter on Response Letter Regarding “An Artificial Neural Network‐Based Model to Predict Chronic Kidney Disease in Aged Cats”
by: Vincent Biourge, et al.
Published: (2025-03-01)

Response to letter regarding “Limited Scope for Latitudinal Extension of Reef Corals”
by: Paul Retson Muir, et al.
Published: (2016-12-01)

Response to letter regarding ‘Cyberattack on the National Health Laboratory Service of South Africa – implications, response and recommendations’
by: S Cassim, et al.
Published: (2025-05-01)

Plasma procalcitonin and C-reactive protein concentrations in dogs with bacterial sepsis and non-infectious systemic inflammatory response syndrome
by: Johanna Rompf, et al.
Published: (2025-06-01)

Lymphocyte subpopulations: a potential predictor of a response in patients with immune thrombocytopenia
by: Kateřina Žibřidová, et al.
Published: (2024-12-01)

Response to the letter
by: N. V. Zhukov
Published: (2022-11-01)

Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses
by: S. V. Akinshina, et al.
Published: (2021-11-01)

Response to Professor Hu Jinyu’s Letter [Response to Letter]
by: Kang X, et al.
Published: (2025-03-01)

The prognostic value of the systemic immune-inflammatory index and the systemic inflammation response index in pediatric immune thrombocytopenia
by: Rehab Elmeazawy, et al.
Published: (2025-05-01)

Thrombocytopenia, immune thrombocytopenia and idiopathic thrombocytopenic purpura
by: Sinasi Ozsoylu
Published: (2010-04-01)

Thrombopoietin Secretion by Human Ovarian Cancer Cells
by: Samaher Besbes, et al.
Published: (2017-01-01)

Response to letter regarding historical maps and violent extremism in Wolkait, Western Tigray, Ethiopia
by: Alene Kassaw, et al.
Published: (2025-12-01)

Identification of prospective novel drug targets for immune thrombocytopenia by integrating plasma proteome
by: Wei He, et al.
Published: (2025-12-01)